🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cerus Corporation (CERS)
NASDAQ: CERS Β· Real-Time Price Β· USD
1.850
-0.050 (-2.63%)
At close: Nov 20, 2026, 4:00 PM EST
1.990
+0.140 (7.57%)
After-hours: Nov 20, 2026, 7:55 PM EST

Cerus Earnings Call Transcripts

Fiscal Year 2026

  • Q3 product revenue rose 10% YoY, with positive adjusted EBITDA for a 10th consecutive quarter and $3 million in operating cash flow. RedeS met its primary efficacy endpoint, while FY 2026 product revenue guidance was reaffirmed at $229 million–$231 million.

  • Q2 2026 saw 10% product revenue growth, strong U.S. and EMEA performance, and improved financials. Guidance for 2026 was raised, with IFC revenue expected to grow 40–50% year-over-year. Debt refinancing lowered costs and increased flexibility.

  • AGM 2026

    The meeting confirmed a quorum, introduced leadership changes, and presented four proposals, all of which were approved by shareholders. No questions were submitted, and voting results will be reported on Form 8-K within four business days.

  • Q1 2026 saw 24% product revenue growth, driven by strong platelet and IFC demand, with raised full-year guidance and continued margin discipline. Innovation and new contracts in the U.S. and EMEA support long-term growth, despite inflation and regulatory uncertainties.

  • INTERCEPT Blood System continues to expand its global leadership in transfusion safety, leveraging strong U.S. and international growth, a robust product pipeline, and strategic partnerships like the BCA agreement. Double-digit revenue growth is expected through 2026, with new product launches and geographic expansion driving future gains.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021